Data Demonstrate Impact of Weight Loss With Sibutramine on Cardiovascular Risk Factors for Obese Patients
26 Mai 2004 - 8:00PM
PR Newswire (US)
Data Demonstrate Impact of Weight Loss With Sibutramine on
Cardiovascular Risk Factors for Obese Patients Data Address
Positive Impact of Weight Loss With Sibutramine on Cardiovascular
Risk Factors of Metabolic Syndrome, Left Ventricular Mass, and
Predicted Risk of Coronary Heart Disease PRAGUE, Czech Republic,
May 26 /PRNewswire-FirstCall/ -- Data presented today at the 13th
European Congress on Obesity explored the reduction of
cardiovascular risk factors associated with being obese among
patients who lost weight with sibutramine treatment. The data
presented at the congress demonstrated the relationship of weight
loss with sibutramine to improvements in obesity-associated
cardiovascular risk factors including metabolic syndrome, reduced
left ventricular mass, and lowered predicted risk of coronary heart
disease (CHD). "Cardiovascular-related conditions including
hypertension, dyslipidaemia and type 2 diabetes are all serious
risks for obese patients," stated Professor Arya M. Sharma M.D.,
Ph.D., Professor of Medicine, Cardiovascular Obesity Research and
Management, at McMaster University in Hamilton, Ontario, Canada.
"These data are significant because they provide insight into the
reduction of cardiovascular risk factors for these obese patients
with sibutramine-induced weight loss." Beneficial Effects in Obese
Patients with Metabolic Syndrome The majority of obese patients
have metabolic syndrome, a condition defined by the presence of
three or more cardiovascular risk factors, which include increased
abdominal fat (measured by waist circumference), dyslipidaemia
(elevated triglyceride levels and reduced HDL cholesterol,
typically known as the 'good' cholesterol), hypertension and
impaired fasting glucose. Analyses of data from obese patients with
metabolic syndrome who participated in five clinical trials with
sibutramine and a reduced-calorie diet showed that after 12 months
of therapy, 58 percent no longer met the criteria for a metabolic
syndrome diagnosis (compared to 40 percent of placebo patients p